Nigel J Dimmock

Summary

Affiliation: University of Warwick
Country: UK

Publications

  1. pmc Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established
    Nigel J Dimmock
    School of Life Sciences, University of Warwick, Coventry, United Kingdom
    PLoS ONE 7:e49394. 2012
  2. pmc Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir
    Nigel J Dimmock
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    Antiviral Res 96:376-85. 2012
  3. ncbi request reprint The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Rev Med Virol 15:365-81. 2005
  4. ncbi request reprint In vivo antiviral activity: defective interfering virus protects better against virulent Influenza A virus than avirulent virus
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry, UK
    J Gen Virol 87:1259-65. 2006
  5. pmc Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry, United Kingdom
    J Virol 82:8570-8. 2008
  6. pmc Defective interfering virus protects elderly mice from influenza
    Paul D Scott
    School of Life Sciences, University of Warwick, Coventry, UK
    Virol J 8:212. 2011
  7. ncbi request reprint Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus
    Paul D Scott
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 92:2122-32. 2011
  8. ncbi request reprint Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing
    Simon Noble
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Vaccine 22:3018-25. 2004
  9. ncbi request reprint Analysis of a 17-amino acid residue, virus-neutralizing microantibody
    Caroline J Heap
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 86:1791-800. 2005
  10. pmc Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo
    Paul D Scott
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    Vaccine 29:6584-91. 2011

Collaborators

  • Andrew J Easton
  • Paul D Scott
  • Bo Meng
  • Tim D Jones
  • Caroline J Heap
  • Steven A Reading
  • Mark J Hollier
  • Linda Cheung
  • Lesley McLain
  • Peter Critchley
  • Simon Noble
  • Sam A Hardy
  • S Matthew Cleveland
  • Dheeraj K Khiytani
  • Teresa J T Pinheiro
  • Keith R Jennings
  • Yuqin Wang
  • Mark Hollier

Detail Information

Publications22

  1. pmc Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established
    Nigel J Dimmock
    School of Life Sciences, University of Warwick, Coventry, United Kingdom
    PLoS ONE 7:e49394. 2012
    ..Together with earlier data from mouse studies, we conclude that 244 DI virus is a highly effective antiviral with activity potentially against all influenza A subtypes...
  2. pmc Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir
    Nigel J Dimmock
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    Antiviral Res 96:376-85. 2012
    ..Treatment with DI virus did not delay clearance or cause persistence of infectious virus or DI RNA. Thus in this system DI virus was overall more effective than oseltamivir in combatting pandemic A/California/04/09...
  3. ncbi request reprint The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Rev Med Virol 15:365-81. 2005
    ..There are lessons here, too, that are relevant to the comprehension of the antigenicity of short protein segments in general...
  4. ncbi request reprint In vivo antiviral activity: defective interfering virus protects better against virulent Influenza A virus than avirulent virus
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry, UK
    J Gen Virol 87:1259-65. 2006
    ..Thus, counter-intuitively, DI virus is most effective against viruses that cause disease with low numbers of particles, i.e. virulent viruses...
  5. pmc Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry, United Kingdom
    J Virol 82:8570-8. 2008
    ..Protecting virus is a novel antiviral, having the potential to combat human influenza virus infections, particularly when the infecting strain is not known or is resistant to antiviral drugs...
  6. pmc Defective interfering virus protects elderly mice from influenza
    Paul D Scott
    School of Life Sciences, University of Warwick, Coventry, UK
    Virol J 8:212. 2011
    ..Homologous protection is mediated by replication competition between the deleted and full-length genomes, and heterologous protection occurs through stimulation of innate immunity, especially interferon type I...
  7. ncbi request reprint Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus
    Paul D Scott
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 92:2122-32. 2011
    ..It was concluded that 244/PR8 has the ability to protect in vivo against heterologous IFN-sensitive respiratory viruses, in addition to homologous influenza A viruses, and that it acts by fundamentally different mechanisms...
  8. ncbi request reprint Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing
    Simon Noble
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Vaccine 22:3018-25. 2004
    ..Thus an interfering vaccine, unlike the conventional vaccine, is independent of the antigenicity of the infecting virus. In principle, interfering vaccines derived from other virus systems could also be developed...
  9. ncbi request reprint Analysis of a 17-amino acid residue, virus-neutralizing microantibody
    Caroline J Heap
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 86:1791-800. 2005
    ..Its equilibrium dissociation constant is 37.5-fold greater than that of IgG, in line with neutralization data. This study demonstrates how MicroAbs can make a useful contribution to the understanding of antigen-antibody interactions...
  10. pmc Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo
    Paul D Scott
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    Vaccine 29:6584-91. 2011
    ..This indicates that the conventional view that DI virus-induced protection is mediated solely by competition for replication with the challenge virus is incorrect for influenza virus...
  11. doi request reprint A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo
    Andrew J Easton
    School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
    Vaccine 29:2777-84. 2011
    ..Protecting virus thus has the potential to protect against all interferon-sensitive respiratory viruses and all influenza A viruses...
  12. ncbi request reprint Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion
    Linda Cheung
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 86:131-8. 2005
    ..Its surface exposure suggests that the gp41 C-terminal tail may be a candidate for immune intervention or chemotherapy of infection...
  13. ncbi request reprint An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion
    Caroline J Heap
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 86:1499-507. 2005
    ..These data confirm the external location of the SAR1 epitope, implicate the gp41 C-terminal tail in the HIV-1 fusion process for the first time, and suggest that SAR1 mediates PAN by inhibiting virus-mediated fusion...
  14. ncbi request reprint A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion
    S Matthew Cleveland
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 84:591-602. 2003
    ..Altogether these data are consistent with part of the C-terminal tail of gp41 being exposed on the outside of the virion. Possible models of the structure of the gp41 tail, taking these observations into account, are discussed...
  15. doi request reprint The receptor preference of influenza viruses
    Bo Meng
    Department of Biological Sciences, University of Warwick, Coventry, UK
    Influenza Other Respir Viruses 4:147-53. 2010
    ..Our aim was to determine a quick and technically simple method to determine cell receptor usage by whole influenza A virus particles...
  16. ncbi request reprint A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of inf
    Steven A Reading
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Virology 315:362-72. 2003
    ..SAR1 is an unusual, if not unique, antibody whose activity supports the view that part of the gp41 C-terminal tail is exposed on the outside of the virion...
  17. pmc Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?
    Nigel J Dimmock
    School of Life Sciences, University of Warwick, Coventry, United Kingdom
    J Virol 88:5217-27. 2014
    ..These data suggest the timeliness of reassessing the potential of DI viruses as a novel class of antivirals that may have general applicability. ..
  18. ncbi request reprint The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function
    Mark J Hollier
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Virology 337:284-96. 2005
    ..The gp41 structural diversity suggested here can be viewed as an evolutionary strategy to minimize HIV-1 envelope glycoprotein expression on the cell surface, and hence possible cytotoxicity and immune attack on the infected cell...
  19. ncbi request reprint Valency of antibody binding to virions and its determination by surface plasmon resonance
    Nigel J Dimmock
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Rev Med Virol 14:123-35. 2004
    ..This review describes how surface plasmon resonance can be used to determine the valency of IgG binding to enveloped and non-enveloped virus particles, and discusses the implications of this new methodology...
  20. pmc Valency of antibody binding to enveloped virus particles as determined by surface plasmon resonance
    Sam A Hardy
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom
    J Virol 77:1649-52. 2003
    ..Where there is a free Fab arm (monovalent binding), a second virus particle is captured. This is detected by surface plasmon resonance. The methodology should be applicable to all enveloped and nonenveloped viruses...
  21. ncbi request reprint Characterization of a human immunodeficiency virus type 1 pre-integration complex in which the majority of the cDNA is resistant to DNase I digestion
    Dheeraj K Khiytani
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    J Gen Virol 83:2523-32. 2002
    ..We conclude that HIV-1 has at least two types of PIC, an early PIC characterized by protein bound only at the LTRs, and a late, and possibly more mature form, in which protein is bound along the length of the cDNA...
  22. ncbi request reprint Binding of an influenza A virus to a neomembrane measured by surface plasmon resonance
    Peter Critchley
    Bioorg Med Chem 12:2773-80. 2004
    ....